ADC Therapeutics S.A.
ADCT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $193,348 | $135,642 | $300,107 | $1,550,314 |
| - Cash | $250,867 | $278,598 | $326,441 | $466,544 |
| + Debt | $122,998 | $124,377 | $117,375 | $101,751 |
| Enterprise Value | $65,479 | -$18,579 | $91,041 | $1,185,521 |
| Revenue | $70,837 | $69,558 | $209,908 | $33,917 |
| % Growth | 1.8% | -66.9% | 518.9% | – |
| Gross Profit | $64,888 | $67,029 | $206,607 | $32,524 |
| % Margin | 91.6% | 96.4% | 98.4% | 95.9% |
| EBITDA | -$102,649 | -$145,827 | -$107,698 | -$230,535 |
| % Margin | -144.9% | -209.6% | -51.3% | -679.7% |
| Net Income | -$157,846 | -$240,053 | -$157,128 | -$230,026 |
| % Margin | -222.8% | -345.1% | -74.9% | -678.2% |
| EPS Diluted | -1.62 | -2.94 | -1.99 | -3 |
| % Growth | 44.9% | -47.7% | 33.7% | – |
| Operating Cash Flow | -$123,835 | -$118,686 | -$138,311 | -$233,378 |
| Capital Expenditures | -$867 | -$3,216 | -$687 | -$6,376 |
| Free Cash Flow | -$124,702 | -$121,902 | -$138,998 | -$239,754 |